© 2005 Oxford University Press
CORRESPONDENCE |
RESPONSE: Re: Locoregional Radiation Therapy in Patients With High-Risk Breast Cancer Receiving Adjuvant Chemotherapy: 20-Year Results of the British Columbia Randomized Trial
Affiliations of authors: McGill University Health Center, Montreal, Quebec, Canada (JR); British Columbia Cancer Agency Radiation Therapy, Systemic Therapy, and Population and Preventive Oncology, Vancouver and Victoria, British Columbia, Canada (IAO, KSW, JJS, RD)
Correspondence to: Joseph Ragaz, MD, FRCPC, McGill University Health Center, Royal Victoria Hospital, Oncology Program, 687 Pine Avenue West, Room A2.04, Montreal, Quebec H3A1A1, Canada (e-mail: joseph.ragaz@mcgill.ca).
| The first 10% of the full text of this article appears below. |
At 20 years of follow-up, we observed a sustained overall mortality reduction of 27% (P = .03) in patients receiving locoregional radiotherapy. The tests of interaction performed for all categories of survival showed no difference between subgroups
Related Correspondence
![]()
CiteULike
Connotea
Del.icio.us What's this?
J Natl Cancer Inst 2005 97: 1162-1163.